pravastatin has been researched along with Experimental Hepatoma in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (66.67) | 18.2507 |
2000's | 1 (33.33) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Blanc, JF; Dugot-Senant, N; Laurendeau, I; Rosenbaum, J; Rullier, A; Taras, D; Vidaud, M | 1 |
Baba, M; Iishi, H; Iseki, K; Nakaizumi, A; Tatsuta, M; Uehara, H; Yamamoto, R; Yano, H | 1 |
Inui, Y; Ishiguro, H; Kakimoto, H; Kawata, S; Matsuzawa, Y; Yamasaki, E | 1 |
3 other study(ies) available for pravastatin and Experimental Hepatoma
Article | Year |
---|---|
Pravastatin reduces lung metastasis of rat hepatocellular carcinoma via a coordinated decrease of MMP expression and activity.
Topics: Animals; Enzyme Inhibitors; Gene Expression; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Neoplasms, Experimental; Lung Neoplasms; Male; Matrix Metalloproteinase 14; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Pravastatin; Rats; Rats, Inbred F344 | 2007 |
Suppression by pravastatin, an inhibitor of p21ras isoprenylation, of hepatocarcinogenesis induced by N-nitrosomorpholine in Sprague-Dawley rats.
Topics: Animals; Anticarcinogenic Agents; Anticholesteremic Agents; Apoptosis; Blotting, Western; Carcinogens; Cholesterol; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Liver Neoplasms, Experimental; Male; Neoplasm Proteins; Nitrosamines; Pravastatin; ras Proteins; Rats; Rats, Sprague-Dawley | 1998 |
Effect of pravastatin, a potent 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, on survival of AH130 hepatoma-bearing rats.
Topics: Animals; Antineoplastic Agents; Cholesterol; Dose-Response Relationship, Drug; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Injections, Intraperitoneal; Liver Neoplasms, Experimental; Male; Neoplasm Transplantation; Pravastatin; Rats; Rats, Inbred Strains | 1992 |